Multiple Sclerosis Drug Market Size & Share, by Disease Type [(Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS)]; Drug Class; Route of Administration; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Multiple Sclerosis Drug Market - Regional Analysis

North America Market Insights

North America multiple sclerosis drug market is anticipated to be the dominating region, with a projected highest share of 48.1% by the end of 2034. The market’s growth in the region is subject to the U.S., readily driving the majority of the demand, further backed by a strong presence of Medicaid and Medicare coverage, accounting for USD 6.5 billion in federal expenditure as of 2024, along with an increase in treatment implementation rates, constituting 75% of diagnosed patients. Besides, an expansion in telemedicine across rural areas, biosimilar adoption diminishing expenses, and the FDA’s fast track approvals of at least 7 new therapies by the end of 2026, are other drivers positively impacting the overall market in the region.

The multiple sclerosis drug market in the U.S. is significantly growing, highly fueled by an increase in the treatment services, catering to 80% of diagnosed patients, along with Medicaid and Medicare coverage extension. Additionally, there has been an increase in federal expenditure by USD 6.2 billion for MS therapies as of 2024, of which the NIH has made an allocation of USD 455 million for conducting neuroprotection research. Besides, Medicare Part B expenditure for monoclonal antibodies also surged by 20% every year, while expanded Medicaid services for DMT have enhanced accessibility to almost 500,250 patients as of 2024, thus effectively uplifting the overall market in the country.

The multiple sclerosis drug market in Canada is also projected to grow at a rate of 6.1%, which is propelled by provincial DMT subsidies and the presence of universal health and medical coverages. Besides, Health Canada has made the provision of USD 3.7 billion, of which 9.5% caters to the federal health budget for MS care facilities as of 2024. Meanwhile, Ontario’s Exceptional Access Program provides complete coverage of high-efficiency DMT expenses, which readily benefits more than 32,000 patients. Furthermore, biosimilar switching policies, indigenous health disparities, and early treatment initiation are other key trends that are skyrocketing the market in the country.

North America's MS drug trade and supply chain facilities (2022-2025)

Sources: FDA Facility Registry, Health Canada, U.S. Dept of Commerce, Canada Biologics Network, Texas Economic Development, NIH Funding Reports

APAC Market Insights

Asia Pacific multiple sclerosis drug market is considered the fastest-growing region, with an expected share of 15.2% during the forecast period. The market’s development in the region is fueled by an increase in government healthcare policies, biosimilar implementation, and a surge in diagnosis volumes. China is positively impacting the region, with a valuation of USD 2.3 billion, owing to the 2023 reforms by the National Medical Products Administration (NMPA) for escalating 7 notable DMT acceptances. India is following closely, with a valuation of USD 920 million through the presence of localized generics and Ayushman Bharat coverage. Then there is a generous investment of USD 750 million by South Korea for conducting neuroprotection, while Malaysia expanded hospital and pharma collaborations through USD 380 million deals, thus suitable for market upliftment in the region.

The multiple sclerosis drug market in China is gaining increased exposure with a projected revenue share of 30.5% within the forecast duration, effectively propelled by administrative policies and enhanced diagnostic rates. The NMPA has readily escalated acceptances for 8 notable DMTs between 2023 and 2024, which include locally developed BTK inhibitors. Besides, there has been a surge in government expenditure by 17.5% on a yearly basis to cater to at least 1.7 million diagnosed patients in the country, of which 66% has been focused on urban locations. Companies in the region, such as Hengrui Pharma, are effectively investing more than USD 205 million in biosimilars, thus creating a huge opportunity for market growth.

The multiple sclerosis drug market in India is also simultaneously growing by an expected 15% of the regional share, which is propelled by administrative policies and generic manufacturing. The CDSCO has successfully approved at least 6 biosimilars as of 2023, which included Biocon’s glatiramer acetate, costing 82% lower than originators. Besides, government spending has increased by 22% since 2020 to an estimated USD 2.4 billion yearly, but out-of-pocket expenses still continue to consume 48% of household health budget for patients suffering from the disorder. Meanwhile, localized players, such as Dr. Reddy, is effectively dominating the market in the country with 62% of the share in generics, thus depicting a huge contribution.

Government Policies and Funding for MS drugs in Australia, Malaysia, and South Korea (2022-2025)

Sources: MS Research Australia, PBS, MOH Malaysia, Pharmacy, MFDS, MFDS

Europe Market Insights

Europe multiple sclerosis drug market is expected to hold a considerable share of 30.2% by the end of the forecast period, catering to a 5.7% growth rate, highly fueled by biosimilar implementation as well as the increased prevalence of the disease. Germany is deliberately leading in the region, with the €4.7 billion in spending as of 2024, which is further driven by AMNOG pricing policies, along with an increase in the yearly growth in demand by 13%. This is followed by the UK allocating 9% of its healthcare budget for MS therapies, along with NICE accepting 8 new DMTs since 2022. In addition, France has provided 7.5% of its budget to support early high-efficiency, thus suitable for the overall market in the region.

The multiple sclerosis drug market in Germany is dominating the region, with a 35% revenue share, accounting for over € 6.5 billion by the end of 2034, which is propelled by an increase in biosimilar adoption and the existence of a value-specific AMNOG pricing system. Besides, the Federal Ministry of Health made the provision of a generous fund that has prioritized early high-efficiency DMTs such as Kesimpta and Ocrevus, further diminishing relapses by 52% in clinical practice. Meanwhile, the EMA’s PRIME scheme has accelerated acceptances for 7 neuroprotection therapies between 2023 and 2025, including Merck’s evobrutinib, thus creating an optimistic outlook for the overall market.

The multiple sclerosis drug market in the UK is also growing, with a projected 25% of the region’s MS drug revenue, accounting for £4.8 billion by the end of the forecast timeline, effectively backed by the NHS universal coverage, as well as NICE’s advanced DMT acceptances. For instance, almost 8.5% of the healthcare budget, which is £2.3 billion as of 2024, has been allocated for MS therapies, including ofatumumab for more than 16,000 patients in the country. Besides, the MHRA’s Innovative Licensing Pathway has reduced approval duration by almost 43%, particularly for drugs such as BTK inhibitors, thus suitable for propelling the overall market.